MindMed

👥 101-250💰 $15.0m Post-IPO Debt on 2023-08-14PharmaceuticalBiotechnologyHealth Care
Website LinkedIn Email Facebook Twitter

MindMed provides psychedelic-inspired medicines and therapies for substance abuse disorders and other mental illnesses. The company is assembling a compelling drug development pipeline of innovative treatments based on psychedelic substances including Psilocybin, LSD, MDMA, DMT, and an Ibogaine derivative, 18-MC.